VIA EDGAR

July 13, 2020

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jeffrey Gabor

Christine Westbrook

Re: Relay Therapeutics, Inc.

Acceleration Request for Registration Statement on Form S-1

File No. 333-239412

Dear Mr. Gabor,

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Relay Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to July 15, 2020, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Gabriela Morales-Rivera at (617) 570-1329. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Gabriela Morales-Rivera, by facsimile to (617) 801-8858.

If you have any questions regarding this request, please contact Gabriela Morales-Rivera of Goodwin Procter LLP at (617) 570-1329.

Sincerely,
RELAY THERAPEUTICS, INC.
	/s/ Sanjiv K. Patel
	Sanjiv K. Patel
	President and Chief Executive Officer

cc: Sanjiv K. Patel, Relay Therapeutics, Inc.

Brian Adams, Relay Therapeutics, Inc.

William D. Collins, Esq., Goodwin Procter LLP

Gabriela Morales-Rivera, Esq., Goodwin Procter LLP